Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · MANGOCEUTICALS, INC. (MGRX)

Mangoceuticals sets Series D preferred stock plan and December 30, 2026 annual meeting

Neutral Impact 3 of 5 financing

Mangoceuticals' sole Series B preferred holder approved terms for a new 8% Series D convertible cumulative preferred stock and an amendment to the Series B designation, which would allow the company to sell up to 1,000,000 shares at $10.00 each under Regulation A. The company said the instruments are not yet filed or effective and it may not proceed with the offering; the company also set its combined 2025 and 2026 annual meeting for December 30, 2026.

Key points

  • On November 2, 2026, the holder of all 50 outstanding Series B preferred shares approved the Series D terms and Series B amendment by written consent.
  • Proposed Series D offering: up to 1,000,000 shares at $10.00 per share under Regulation A; no sales will occur before the SEC qualifies the offering statement on Form 1-A.
  • Annual meeting set for December 30, 2026 in Dallas, Texas; record date is November 12, 2026.
  • Shareholder proposals and director nominations for the meeting are due by November 16, 2026.

The filing

CompanyMANGOCEUTICALS, INC. (MGRX)
Form8-K, current report
Filed with the SECNov 6, 2026, 5:25 PM ET
Accession number0001493152-26-050533

Items reported: 5.07 Shareholder Vote Results5.08 Shareholder Director Nominations8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 7:05 AM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.